JUL 26, 2018 10:30 PM PDT

Cannabinoids for Dementia

WRITTEN BY: Mauri Brueggeman

One area of interest in the last year, as medical cannabis moves into the mainstream, is the use of cannabinoids for the treatment of dementia.  To be clear, many of the scientists or providers looking to cannabis or cannabinoid products are really looking at treating the symptoms associated with dementia, rather than the cause of dementia itself.  According to the literature, around half of patients with dementia experience behavioral and psychological symptoms (BPSD) which are distressing for everyone involved including the patient, caregivers, and family.  While it is widely accepted to use anti-psychotics for these patients, many patients do not show significant improvement and suffer grave side effects as a result of that group of pharmaceuticals used.

There are many scientists itching to explore the use of cannabinoids for the treatment of dementia because of their connection to our own endocannabinoid system (ECS), which maintains many physiological balances within our bodies.  There have been multiple neurological benefits connected to and documented as being a result of cannabinoid presence in the body.  One of the critical roles of the ECS is regulation of message transmission via our cellular synapses.  The ECS has multiple components: already somewhat understood endocannabinoids including 2-arachidonoyl glycerol (2-AG) and anandamide, cannabinoid receptors (CB1 and CB2), and enzymes involved in the regulation and metabolism of endocannabinoids.

Phytocannabinoids, like tetrahydrocannabinol (THC) and cannabidiol (CBD), affect the ECS through use or agonistic action on the cannabinoid receptors located in the body.  It has been suggested that some of these ECS components, CB2 for example, have specific neuroprotection features and that these neuroprotective effects counteract the neurodegenerative process involved in many forms of dementia.  Researchers have even documented reduction in CB1 levels within the nervous system of patients with dementia.  One group of researchers found changes in expression and distribution of CB1 in Alzheimer’s patients.  In fact, THC decreases the amyloid beta-peptide aggregates characteristically found in Alzheimer’s patients.  In these data sets, the research points to cannabinoids having a direct effect on the pathogenesis of disease. 

In other types of dementia where pathogenesis is less well understood, cannabinoids have been suggested to provide relief from the common BPSD felt by patients and those close to them including depression, anxiety, agitation, aggression, wandering, issues sleeping, and others. 

Sources: Neurodegenerative Disease Management, Cochrane Database of Systematic Reviews,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
SEP 06, 2019
Health & Medicine
SEP 06, 2019
Cannabis Holds Promise in Aiding PTSD
Cannabinoids, the active components of the cannabis plant, may have the potential to treat PTSD by reducing nightmares and aiding poor sleep habits. Howeve...
NOV 18, 2019
Cannabis Sciences
NOV 18, 2019
Frequent Marijuana Use Linked with Stroke and Arrhythmia
Research from two new preliminary studies presented at the American Heart Association’s (AHA) annual Scientific Sessions this week warned of the heal...
DEC 03, 2019
Cannabis Sciences
DEC 03, 2019
Cannabis Dependence Poses Danger for Post-op Heart Attacks
People undergoing common surgeries are immediately at an increased risk for post-op heart attack and potentially stroke if they have any link to cannabis d...
DEC 20, 2019
Health & Medicine
DEC 20, 2019
Potential Link Between Cannabis Use and Structural Changes to the Heart
Researchers from the Queen Mary University of London used MRI images of more than 3,000 people, 152 of them former or current cannabis users, to identify a...
JAN 29, 2020
Cannabis Sciences
JAN 29, 2020
In Sicily, Medical Cannabis Is Now Free
The Sicilian government will now foot the bill for many patients using medical cannabis. Sicily’s top health administrator, Ruggero Razza, announced...
FEB 12, 2020
Cannabis Sciences
FEB 12, 2020
Insurance for Cannabis? Coverage Remains Elusive
Cannabis use can carry a variety of benefits and risks for recreational consumers, patients, doctors and businesses. And where there is risk, there is ofte...
Loading Comments...